FDA accepts Sanofi’s New Drug Application for basal insulin Toujeo®
8 July 2014 | By Sanofi
Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for Toujeo®...
List view / Grid view
News
Japan approves first all-oral, interferon- and ribavirin-free hepatitis C treatment, daklinza® (daclatasvir) and sunvepra® (asunaprevir) dual regimen
7 July 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza® (daclatasvir)...
Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience
7 July 2014 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary...
Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
4 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases...
Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
Marketing and manufacturing approval in Japan received for CANAGLU® tablets 100mg
4 July 2014 | By Daiichi Sankyo
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU® tablets 100mg (generic name: canagliflozin hydrate, hereafter, CANAGLU®) in Japan, for the treatment of patients with type 2 diabetes mellitus...
Teva receives CHMP positive opinion for Seasonique® extended-regimen contraceptive for marketing authorization in several European countries
4 July 2014 | By Teva
An extended regimen oral contraceptive that provides quarterly menses – a new concept for women in Europe...
Prime Minister warns of global threat of antibiotic resistance
3 July 2014 | By Department of Health
The Prime Minister David Cameron called for global action to tackle the growing threat of resistance to antibiotics...
Ebola cases in West Africa continue to rise
3 July 2014 | By Public Health England
PHE and other stakeholders providing technical support to the affected countries...
Mass spectrometry-based metabolics – an exclusive online-only article from Tun-Li Shen at Brown University
3 July 2014 | By Tun-Li Shen, Brown University
Tun-Li Shen provides a brief overview of the gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) instrumentation platforms used in untargeted metabolomics studies...
GSK statement on UK Government-initiated review of antibiotic resistance
3 July 2014 | By GlaxoSmithKline
“We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance..."
Midatech appoints Nick Robbins-Cherry as Finance Director
2 July 2014 | By Midatech
Midatech Ltd. is pleased to announce that Nick Robbins-Cherry has been appointed as Finance Director, further strengthening the Company’s senior management team...
Pfizer Inc. receives kosher certification for Elelyso™ (taliglucerase alfa) for injection, for the treatment of Type 1 Gaucher disease
2 July 2014 | By Pfizer
Pfizer Inc. announced that the Orthodox Union has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease...
Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD
2 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler...
Roche announces definitive agreement to acquire Seragon Pharmaceuticals
2 July 2014 | By Roche
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer...
